EZH2 and acute myeloid leukemia: In the VCU Massey Cancer Center Project ERIS database involving 600 patients with AML, 28.9% harbored a spliceosome mutation or a mutation in BCOR, EZH2, or STAG2; 36.8% harbored mutations in any of the seven previously mentioned genes or ASXL1 or RUNX1 (Figure 1).